Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Liposarcoma × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Recurrence 5 Glioblastoma 4 Leukemia, Myeloid, Acute 3 Colorectal Neoplasms 3 Neoplasms, Plasma Cell 2 Melanoma 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioma 2 Carcinoma, Squamous Cell 2 Brain Neoplasms 2 Astrocytoma 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Thymoma 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Richter's Transformation 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1

Interventions

Doxorubicin 6 pazopanib 4 Trabectedin 4 Radiotherapy 3 temsirolimus 2 eribulin 2 Sunitinib 2 Radiotherapy, Conformal 2 Ifosfamide 2 Dexamethasone 2 sitravatinib 1 selinexor 1 saracatinib 1 romidepsin 1 regorafenib 1 plitidepsin 1 pembrolizumab 1 palbociclib 1 olaratumab 1 milademetan 1 liposomal doxorubicin 1 lenvatinib 1 indolepropanol phosphate 1 efatutazone 1 cixutumumab 1 brigimadlin 1 avelumab 1 atezolizumab 1 Watchful Waiting 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡